Article

Phentermine plus topiramate in the treatment of obesity

The Lancet (Impact Factor: 39.21). 07/2011; 378(9786):126; author reply 126-7. DOI: 10.1016/S0140-6736(11)61081-7
Source: PubMed
0 Followers
 · 
38 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article is a report on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the Experimental Biology 12 meeting in San Diego, CA. The presentations discussed the roles of a number of nuclear receptors in regulating glucose and lipid homeostasis, the pathophysiology of obesity-related disease states and the promise associated with targeting their activities to treat these diseases. While many of these receptors, in particular constitutive androstane receptor and pregnane X receptor and their target enzymes have been thought of as regulators of drug and xenobiotic metabolism, this symposium highlighted the advances made in our understanding of the endogenous functions of these receptors. Similarly, the advances made in our understanding of the mechanisms underlying bile acid signaling pathways in the regulation of body weight and glucose homeostasis illustrates the importance of using complementary approaches to elucidate this fascinating network of pathways. The observations that some receptors, like the farnesoid X receptor can function in a tissue specific manner via well defined mechanisms has important clinical implications particularly in the treatment of liver diseases. Finally, the novel findings that agents that selectively activate estrogen receptor β can effectively inhibit weight gain in a high-fat diet model of obesity identifies a new role for this member of the steroid superfamily. Taken together, this symposium has revealed a number of significant findings that illustrate the promise associated with targeting a number of nuclear receptors for the development of new therapies to treat obesity and other metabolic disorders.
    Drug metabolism and disposition: the biological fate of chemicals 10/2012; 41(1). DOI:10.1124/dmd.112.048694 · 3.33 Impact Factor
  • Source
    Circulation Cardiovascular Quality and Outcomes 07/2012; 5(4):580-6. DOI:10.1161/CIRCOUTCOMES.111.964072 · 5.04 Impact Factor